CohBar, Inc. (CWBR)

$2.73

-0.09 (-3.19%)
Rating:
Recommendation:
Neutral
Symbol CWBR
Price $2.73
Beta 1.792
Volume Avg. 0.03M
Market Cap 7.936M
Shares () -
52 Week Range 1.5-10.53
1y Target Est -
DCF Unlevered CWBR DCF ->
DCF Levered CWBR LDCF ->
ROE -108.34% Strong Sell
ROA -123.65% Strong Sell
Operating Margin -
Debt / Equity 2.92% Neutral
P/E -
P/B 0.42 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CWBR news


Mr. Steven Engle
Healthcare
Biotechnology
NASDAQ Capital Market

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.